Atreca, Inc. - (BCEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
BCEL Stock Price Chart Interactive Chart >
BCEL Price/Volume Stats
| Current price | $1.57 | 52-week high | $5.36 |
| Prev. close | $1.58 | 52-week low | $0.76 |
| Day low | $1.54 | Volume | 46,700 |
| Day high | $1.59 | Avg. volume | 209,394 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $1.73 | Market Cap | 61.34M |
Atreca, Inc. - (BCEL) Company Bio
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.
Latest BCEL News From Around the Web
Below are the latest news stories about ATRECA INC that investors may wish to consider to help them evaluate BCEL as an investment opportunity.
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Atreca Appoints Philippe Bishop, MD as Chief Medical OfficerSAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. “Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATR |
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline UpdateSAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. "The third quarter was a productiv |
Atreca to Present at Upcoming Investor ConferencesSAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences: Cowen 6th Annual IO Next SummitNovember 11, 2022Fireside Chat: 2:40-3:00 am EST, November 11, 2022 Stifel Healthcare ConferenceNovember 15-16, 202 |
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual MeetingSAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2022 Annual Meeting, being held November 8-12 in Boston, Massachusetts. Details are as follows: Title: Interim Clinical Update of the Phase 1b Trial of ATRC-101 as Monot |
BCEL Price Returns
| 1-mo | 98.73% |
| 3-mo | 4.67% |
| 6-mo | -20.30% |
| 1-year | -9.77% |
| 3-year | -91.52% |
| 5-year | N/A |
| YTD | 96.10% |
| 2022 | -73.58% |
| 2021 | -81.24% |
| 2020 | 4.40% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...